TABLE 3.
Circulating concentrations of sex steroid hormones by COMT genotype in postmenopausal women randomly assigned to the GTE or placebo group1
| COMT genotype | |||||||
|---|---|---|---|---|---|---|---|
| Sex hormone | G/G (n = 248) | A/A (n = 300) | G/A (n = 389) | ||||
| Time point | GTE (n = 126) | PLC (n = 122) | GTE (n = 156) | PLC (n = 144) | GTE (n = 181) | PLC (n = 208) | P 2 |
| Estrone, pg/mL | — | — | — | — | — | — | 0.71 |
| Baseline | 23.5 (21.4, 25.7) | 24.1 (22.0, 26.5) | 22.2 (20.3, 24.3) | 22.3 (20.3, 24.5) | 22.7 (20.9, 24.7) | 24.4 (22.6, 26.3) | |
| Month 12 | 24.1 (21.8, 26.8) | 23.5 (21.2, 26.1) | 22.4 (20.6, 24.3) | 21.9 (20.1, 23.9) | 21.3 (19.6, 23.1) | 22.3 (20.7, 24.0) | |
| Estradiol, pg/mL | — | — | — | — | — | — | 0.53 |
| Baseline | 3.3 (2.7, 4.0) | 3.2 (2.6, 3.9) | 3.5 (3.0, 4.2) | 3.7 (3.1, 4.4) | 3.3 (2.8, 3.9) | 4.0 (3.4, 4.7) | |
| Month 12 | 4.1 (3.3, 5.0) | 3.0 (2.4, 3.7) | 3.4 (2.9, 4.0) | 3.3 (2.8, 3.8) | 3.8 (3.3, 4.4) | 3.2 (2.7, 3.6) | |
| Bioavailable estradiol, pg/mL | — | — | — | — | — | — | 0.54 |
| Baseline | 1.5 (1.2, 1.8) | 1.4 (1.2, 1.8) | 1.6 (1.3, 1.9) | 1.6 (1.4, 2.0) | 1.5 (1.2, 1.8) | 1.8 (1.6, 2.2) | |
| Month 12 | 1.9 (1.5, 2.3) | 1.3 (1.1, 1.7) | 1.5 (1.3, 1.8) | 1.5 (1.2, 1.7) | 1.7 (1.5, 2.0) | 1.5 (1.3, 1.7) | |
| Androstenedione, pg/mL | — | — | — | — | — | — | 0.51 |
| Baseline | 480 (440, 523) | 490 (449, 534) | 484 (448, 522) | 501 (462, 542) | 478 (447, 511) | 521 (490, 555) | |
| Month 12 | 494 (461, 530) | 479 (446, 514) | 453 (420, 489) | 468 (432, 506) | 467 (439, 496) | 487 (460, 516) | |
| Testosterone, pg/mL | — | — | — | — | — | — | 0.95 |
| Baseline | 158 (143, 174) | 173 (157, 190) | 147 (133, 162) | 155 (140, 172) | 149 (135, 164) | 161 (147, 176) | |
| Month 12 | 165 (150, 181) | 159 (145, 174) | 152 (138, 168) | 151 (136, 167) | 158 (145, 172) | 157 (145, 170) | |
| Bioavailable testosterone, pg/mL | — | — | — | — | — | — | 0.84 |
| Baseline | 40.1 (36.0, 44.6) | 44.4 (39.8, 49.4) | 37.2 (33.3, 41.5) | 39.0 (34.8, 43.8) | 38.2 (34.5, 42.3) | 42.4 (38.6, 46.7) | |
| Month 12 | 43.0 (39.0, 47.5) | 40.4 (36.6, 44.7) | 38.3 (34.4, 42.7) | 38.3 (34.2, 42.8) | 40.9 (37.2, 45.1) | 41.9 (38.3, 45.9) | |
| SHBG, nmol/L | — | — | — | — | — | — | 0.97 |
| Baseline | 70.2 (64.5, 76.3) | 69.4 (63.7, 75.5) | 68.8 (64.3, 73.6) | 71.6 (66.7, 76.8) | 66.8 (62.2, 71.7) | 66.5 (62.3, 71.1) | |
| Month 12 | 67.9 (62.5, 73.9) | 70.5 (64.8, 76.7) | 71.4 (66.6, 76.5) | 70.8 (65.8, 76.1) | 67.7 (62.7, 73.0) | 65.5 (61.1, 70.3) | |
1 n = 937. Values are geometric means (95% CIs). COMT, catechol-O-methyltransferase; GTE, green tea extract; PLC, placebo; SHBG, sex hormone-binding globulin.
2 P values for the interaction between treatment and COMT genotype derived from a mixed-effects repeated-measures ANOVA with adjustment for age and BMI at baseline.